abstract: UNASSIGNED: Simultaneous inhibition of @entity7 and @entity8 via the common receptor chain @entity9 to block adequately their biologic effects presents a promising therapeutic approach to give the additional relief required for @entity3 @entity0 . In this study, superparamagnetic @entity6 nanoparticles were conjugated with anti- @entity9 blocking antibodies via @entity4 ( @entity5 ) polymers. The delivery of these blocking antibodies to the inflammatory sites in the lung via the developed nanocarriers was assessed using noninvasive free-breathing pulmonary MRI. Biocompatibility assays confirmed the safety of the developed nanocarriers for pre-clinical investigations. For all the investigated formulations, nanocarriers were found to be very stable at neutral pH. However, the stability noticeably decreased with the @entity5 length in acidic environment and thus the loaded antibodies were preferentially released. Immunofluorescence and fluorimetry assays confirmed the binding of the nanocarriers to the @entity9 @entity3 biomarker. Pulmonary MRI performed using an ultra-short echo time sequence allowed simultaneous noninvasive monitoring of inflammatory responses induced by @entity10 challenge and tracking of the developed nanocarriers, which were found to colocalize with the inflammatory sites in the lung. Targeting of the developed nanocarriers to areas rich in @entity9 positive inflammatory cells was confirmed using histological and flow cytometry analyses. The anti- @entity9 -conjugated nanocarriers developed here have been confirmed to be efficient in targeting key inflammatory cells during chronic @entity2 following intrapulmonary administration. Targeting efficiency was monitored using noninvasive MRI, allowing detection of the nanocarriers' colocalizations with the inflammatory sites in the lung of @entity10 -challenged asthmatic @entity1 . Copyright    2015 John Wiley _ Sons, Ltd.

title: Specific targeting and noninvasive magnetic resonance imaging of an XXXX biomarker in the lung using @entity4 functionalized magnetic nanocarriers.

answer: @entity3


abstract: Prayer is one kind of worship that is composed of repetitive action during praying in Islam. The prayer is performed five times a day, every Friday, bairams and @entity2 ceremonies. The aim of this study is to search the role of this repetitive action on knee, @entity3 and @entity1 . Forty-six @entity0 who had been performing the prayer at least for 10 years, and 40 @entity0 who had not performed the prayer, were included in this prospective study. Each @entity0 was evaluated with standard questionnaire form, joint examination was done and various laboratory parameters were studied. Anterior-posterior radiography of the pelvis and weight-bearing knees of each @entity0 were examined. Each film was evaluated by two investigators separately and first scored by using Kellgren and Lawrence (K_L) scale, then the width of the joint space of hips and knees were measured directly using a steel ruler and recorded to the nearest half millimeter. Bone mineral density (BMD) of lumbar spine and femur was measured. @entity0 having Heberden's nodes, @entity5 , and carpometacarpal disease were frequent in worshiper group. Joint space width measurements and assessment according to K_L scale did not differ between worshipers and non-worshipers. BMD of lumbar spine was decreased in worshipers and also decreased with @entity0 having Heberden's nodes, @entity5 , female gender and age. Prayer has no effect on knee and @entity3 , and may be related with @entity4 . It seems to have negative effect on lumbar BMD, but further investigations are needed.

title: Effect of prayer on @entity4 and XXXX .

answer: @entity1


abstract: Prayer is one kind of worship that is composed of repetitive action during praying in Islam. The prayer is performed five times a day, every Friday, bairams and @entity2 ceremonies. The aim of this study is to search the role of this repetitive action on knee, @entity3 and @entity1 . Forty-six @entity0 who had been performing the prayer at least for 10 years, and 40 @entity0 who had not performed the prayer, were included in this prospective study. Each @entity0 was evaluated with standard questionnaire form, joint examination was done and various laboratory parameters were studied. Anterior-posterior radiography of the pelvis and weight-bearing knees of each @entity0 were examined. Each film was evaluated by two investigators separately and first scored by using Kellgren and Lawrence (K_L) scale, then the width of the joint space of hips and knees were measured directly using a steel ruler and recorded to the nearest half millimeter. Bone mineral density (BMD) of lumbar spine and femur was measured. @entity0 having Heberden's nodes, @entity5 , and carpometacarpal disease were frequent in worshiper group. Joint space width measurements and assessment according to K_L scale did not differ between worshipers and non-worshipers. BMD of lumbar spine was decreased in worshipers and also decreased with @entity0 having Heberden's nodes, @entity5 , female gender and age. Prayer has no effect on knee and @entity3 , and may be related with @entity4 . It seems to have negative effect on lumbar BMD, but further investigations are needed.

title: Effect of prayer on XXXX and @entity1 .

answer: @entity4


abstract: A feed-forward neural network was investigated to predict the occurrence of lung radiation-induced Grade 2+ @entity2 . The database consisted of 235 @entity0 with @entity1 treated using radiotherapy, of whom 34 were diagnosed with Grade 2+ @entity2 at follow-up. The network was constructed using an algorithm that alternately grew and pruned it, starting from the smallest possible network, until a satisfactory solution was found. The weights and biases of the network were computed using the error back-propagation approach. Momentum and variable leaning techniques were used to speed convergence. Using the growing/pruning approach, the network selected features from 66 dose and 27 non-dose variables. During network training, the 235 @entity0 were randomly split into ten groups of approximately equal size. Eight groups were used to train the network, one group was used for early stopping training to prevent overfitting, and the remaining group was used as a test to measure the generalization capability of the network (cross-validation). Using this methodology, each of the ten groups was considered, in turn, as the test group (ten-fold cross-validation). For the optimized network constructed with input features selected from dose and non-dose variables, the area under the receiver operating characteristics (ROC) curve for cross-validated testing was 0.76 (sensitivity: 0.68, specificity: 0.69). For the optimized network constructed with input features selected only from dose variables, the area under the ROC curve for cross-validation was 0.67 (sensitivity: 0.53, specificity: 0.69). The difference between these two areas was statistically significant (p = 0.020), indicating that the addition of non-dose features can significantly improve the generalization capability of the network. A network for prospective testing was constructed with input features selected from dose and non-dose variables (all data were used for training). The optimized network architecture consisted of six input nodes (features), four hidden nodes, and one output node. The six input features were: lung volume receiving > 16 Gy (V16), generalized equivalent uniform dose (gEUD) for the exponent a = 1 (mean lung dose), gEUD for the exponent a = 3.5, free expiratory volume in 1 s (FEV1), diffusion capacity of @entity3 (DLCO%), and whether or not the @entity0 underwent chemotherapy prior to radiotherapy. The significance of each input feature was individually evaluated by omitting it during network training and gauging its impact by the consequent deterioration in cross-validated ROC area. With the exception of FEV1 and whether or not the @entity0 underwent chemotherapy prior to radiotherapy, all input features were found to be individually significant (p < 0.05). The network for prospective testing is publicly available via internet access.

title: A neural network model to predict lung radiation-induced XXXX .

answer: @entity2


abstract: OBJECTIVE. We investigated the feasibility of delivering an individualized, progressive, high-repetition @entity2 ( @entity2 ) task-specific training protocol for @entity0 with @entity1 in the inpatient rehabilitation setting. METHOD. Fifteen @entity0 with @entity2 paresis participated in this study. Task-specific @entity2 training was scheduled for 60 min/day, 4 days/wk, during occupational therapy for the duration of a @entity0 's inpatient stay. During each session, @entity0 were challenged to complete >= 300 repetitions of various tasks. RESULTS. @entity0 averaged 289 repetitions/session, spending 47 of 60 min in active training. @entity0 improved on impairment and activity level outcome measures. CONCLUSION. @entity0 with @entity1 in an inpatient setting can achieve hundreds of repetitions of task-specific training in 1-hr sessions. As expected, all @entity0 improved on functional outcome measures. Future studies are needed to determine whether this high-repetition training program results in better outcomes than current @entity2 interventions.

title: Feasibility of high-repetition, task-specific training for individuals with XXXX paresis.

answer: @entity2


abstract: @entity3 ( @entity3 ) continue to be a major cause of concern after cardiac surgery. It leads to prolonged hospital stay and increased morbidity, mortality and increased hospital costs. Prophylactic systemic antibiotics have been used to prevent @entity1 ( @entity1 ). However, prolonged postoperative use of systemic antibiotics can lead to emergence of resistant organisms. @entity2 Containing Collagen Implants (GCCI) when used during sternotomy closure produces high local antibiotic concentrations in the wound with a low serum concentration. There is evidence that the concentration of @entity2 in the mediastinal fluid reaches levels high enough to be effective against bacteria that are considered resistant to @entity2 and other antibiotics.However, questions have been raised about the safety and efficacy of GCCI. There were concerns whether GCCI can lead to systemic absorption with @entity0 and whether use of topical antibiotics can lead to emergence of antimicrobial resistance.We, hereby, review the literature on GCCI (Collatamp) and take the opportunity to appraise the scientific community about their role in cardiac surgery. Several recent studies have supported their clinical effectiveness. They should be used in dry condition and should not be soaked in saline even for a short period prior to use. However, for GCCI to become part of routine practice in cardiac surgery further large randomised studies are required. As the incidence of sternal wound infection is low in the specialty of cardiac surgery, for any study to be sufficiently powered to address this issue, multicenter studies might be the way forward.Based on the evidence presented in this manuscript it is recommended GCCI (Collatamp) can be a cost effective adjunct for prevention of sternal wound infection. They can also be used for treatment of @entity3 .

title: Role of topical application of XXXX containing collagen implants in cardiac surgery.

answer: @entity2


abstract: OBJECTIVE: Small anterior communicating @entity1 with recurrent @entity3 and adjacent @entity5 may have a high risk of post-operative rebleeding. This clinical study summarizes our preliminary experience with this subset of @entity2 , which were treated with endovascular coiling and subsequent Onyx 34 @entity4 . METHODS: We retrospectively reviewed the data of 9 @entity0 suffering from small anterior communicating @entity1 treated with the combination of coils and Onyx. The clinical characteristics, angiographic outcomes, and follow-up results are reviewed. RESULTS: Endovascular coiling and Onyx @entity4 were successfully accomplished in all 9 cases. The Raymond scale ratings of the treatments are all class I with the parent arteries kept patent. One @entity0 died of severe @entity6 on the 5th post-operative day. The modified Rankin scale (mRS) score for the other 8 @entity0 at follow-ups (6m to 26m, 15.8m on average) was 0 in 5 cases, 1 in 2 cases, and 3 in 1 case. Seven of 8 @entity0 (87.5%) underwent angiographic follow-up that demonstrated persistent durable occlusion with no recanalization. CONCLUSIONS: Endovascular coiling and subsequent Onyx 34 @entity4 may be effective in treating anterior communicating @entity1 with adjacent @entity5 . Further studies with larger sample size and adequate follow-up are required to verify its safety and efficacy as well as to evaluate the long-term outcome.

title: Application of endovascular coiling and subsequent Onyx 34 XXXX in anterior communicating @entity1 with adjacent @entity5 .

answer: @entity4


abstract: OBJECTIVE: Small anterior communicating @entity1 with recurrent @entity3 and adjacent @entity5 may have a high risk of post-operative rebleeding. This clinical study summarizes our preliminary experience with this subset of @entity2 , which were treated with endovascular coiling and subsequent Onyx 34 @entity4 . METHODS: We retrospectively reviewed the data of 9 @entity0 suffering from small anterior communicating @entity1 treated with the combination of coils and Onyx. The clinical characteristics, angiographic outcomes, and follow-up results are reviewed. RESULTS: Endovascular coiling and Onyx @entity4 were successfully accomplished in all 9 cases. The Raymond scale ratings of the treatments are all class I with the parent arteries kept patent. One @entity0 died of severe @entity6 on the 5th post-operative day. The modified Rankin scale (mRS) score for the other 8 @entity0 at follow-ups (6m to 26m, 15.8m on average) was 0 in 5 cases, 1 in 2 cases, and 3 in 1 case. Seven of 8 @entity0 (87.5%) underwent angiographic follow-up that demonstrated persistent durable occlusion with no recanalization. CONCLUSIONS: Endovascular coiling and subsequent Onyx 34 @entity4 may be effective in treating anterior communicating @entity1 with adjacent @entity5 . Further studies with larger sample size and adequate follow-up are required to verify its safety and efficacy as well as to evaluate the long-term outcome.

title: Application of endovascular coiling and subsequent Onyx 34 @entity4 in anterior communicating @entity1 with adjacent XXXX .

answer: @entity5


abstract: OBJECTIVE: Small anterior communicating @entity1 with recurrent @entity3 and adjacent @entity5 may have a high risk of post-operative rebleeding. This clinical study summarizes our preliminary experience with this subset of @entity2 , which were treated with endovascular coiling and subsequent Onyx 34 @entity4 . METHODS: We retrospectively reviewed the data of 9 @entity0 suffering from small anterior communicating @entity1 treated with the combination of coils and Onyx. The clinical characteristics, angiographic outcomes, and follow-up results are reviewed. RESULTS: Endovascular coiling and Onyx @entity4 were successfully accomplished in all 9 cases. The Raymond scale ratings of the treatments are all class I with the parent arteries kept patent. One @entity0 died of severe @entity6 on the 5th post-operative day. The modified Rankin scale (mRS) score for the other 8 @entity0 at follow-ups (6m to 26m, 15.8m on average) was 0 in 5 cases, 1 in 2 cases, and 3 in 1 case. Seven of 8 @entity0 (87.5%) underwent angiographic follow-up that demonstrated persistent durable occlusion with no recanalization. CONCLUSIONS: Endovascular coiling and subsequent Onyx 34 @entity4 may be effective in treating anterior communicating @entity1 with adjacent @entity5 . Further studies with larger sample size and adequate follow-up are required to verify its safety and efficacy as well as to evaluate the long-term outcome.

title: Application of endovascular coiling and subsequent Onyx 34 @entity4 in anterior communicating XXXX with adjacent @entity5 .

answer: @entity1


abstract: BACKGROUND: Integrating mental health with general medical care can increase access to mental health services, but requires helping generalists acquire a range of unfamiliar knowledge and master potentially complex diagnostic and treatment processes. METHOD: We describe a model for integrating complex specialty care with generalist/primary care, using as an illustration the integration of mental health into hospital-based @entity3 treatment services in Ethiopia. Generalists and specialists collaboratively developed mental health treatments to fit the knowledge, skills and resources of the generalists. The model recognizes commonalities between mental health and general medical care, focusing on practical interventions acceptable to @entity0 . It was developed through a process of literature review, interviews, observing clinical practice, pilot trainings and expert consultation. Preliminary evaluation results were obtained by debriefing generalist trainees after their return to their clinical sites. RESULTS: In planning interviews, generalists reported discomfort making mental health diagnoses but recognition of symptom groups including low mood, @entity1 , thought problems, poor @entity0 behaviour, @entity2 and substance use. Diagnostic and treatment algorithms were developed for these groups and tailored to the setting by including possible medical causes and burdens of living with @entity3 . First-line treatment included modalities familiar to generalists: empathetic @entity0 -provider interactions, psychoeducation, cognitive reframing, referral to community supports and elements of symptom-specific evidence-informed counselling. Training introduced basic skills, with evolving expertise supported by job aides and ongoing support from mental health nurses cross-trained in @entity3 testing. Feedback from trainees suggested the programme fit well with generalists' settings and clinical goals. CONCLUSIONS: An integration model based on collaboratively developing processes that fit the generalist setting shows promise as a method for incorporating complex, multi-faceted interventions into general medical settings. Formal evaluations will be needed to compare the quality of care provided with more traditional approaches and to determine the resources required to sustain quality over time.

title: Collaboratively reframing mental health for integration of XXXX care in Ethiopia.

answer: @entity3


abstract: BACKGROUND: Understanding the risk factors for @entity3 after knee replacement could help to reduce the risk of mortality after this procedure. We assessed secular trends in @entity3 within 45 days of knee replacement for @entity5 in England and Wales, with the aim of investigating whether any change that we recorded could be explained by alterations in modifiable perioperative factors. METHODS: We took data for knee replacements done for @entity5 in England and Wales between April 1, 2003, and Dec 31, 2011, from the National Joint Registry for England and Wales. @entity0 identifiers were used to link these data to the national mortality database and the Hospital Episode Statistics database to obtain details of @entity3 , sociodemographics, and comorbidity. We assessed mortality within 45 days by Kaplan-Meier analysis and assessed the role of @entity0 and treatment factors by Cox proportional hazards models. FINDINGS: 467,779 primary knee replacements were done to treat @entity5 during 9 years. 1183 @entity0 died within 45 days of surgery, with a substantial secular decrease in mortality from 0  37% in 2003 to 0  20% in 2011, even after adjustment for age, sex, and comorbidity. The use of unicompartmental knee replacement was associated with substantially lower mortality than was total knee replacement (hazard ratio [HR] 0  32, 95% CI 0  19   0  54, p<0  0005). Several comorbidities were associated with increased mortality: @entity6 (HR 3  46, 95% CI 2  81   4  14, p<0  0005), @entity2 (3  35, 2  7   4  14, p<0  0005), moderate/severe @entity4 (7  2, 3  93   13  21, p<0  0005), and @entity1 (2  18, 1  76   2  69, p<0  0005). Modifiable perioperative risk factors, including surgical approach and thromboprophylaxis were not associated with mortality. INTERPRETATION: Postoperative mortality after knee replacement has fallen substantially between 2003 and 2011. Efforts to further reduce mortality should concentrate more on older @entity0 , those who are male and those with specific comorbidities, such as @entity6 , @entity2 , @entity4 , and @entity1 . FUNDING: National Joint Registry for England and Wales.

title: 45-day mortality after 467,779 knee replacements for XXXX from the National Joint Registry for England and Wales: an observational study.

answer: @entity5


abstract: @entity0 with @entity9 ( @entity9 ), an inherited salt-losing tubulopathy, are usually treated with @entity4 -sparing diuretics or nonsteroidal anti-inflammatory drugs and oral @entity4 and @entity7 supplementations. However, evidence supporting these treatment options is limited to case series studies. We designed an open-label, randomized, crossover study with blind end point evaluation to compare the efficacy and safety of 6-week treatments with one time daily 75 mg slow-release @entity8 , 150 mg @entity11 , or 20 mg @entity10 added to constant @entity4 and @entity7 supplementation in 30 @entity0 with @entity9 (individual participation: 48 weeks). Baseline plasma @entity4 concentration was 2.8  0.4 mmol/L and increased by 0.38 mmol/L (95% confidence interval [95% CI], 0.23 to 0.53; P<0.001) with @entity8 , 0.15 mmol/L (95% CI, 0.02 to 0.29; P=0.03) with @entity11 , and 0.19 mmol/L (95% CI, 0.05 to 0.33; P<0.01) with @entity10 . Fifteen @entity0 became normokalemic: six with @entity8 , three with @entity11 , and six with @entity10 . @entity8 significantly reduced @entity1 and plasma @entity3 concentration. @entity11 and @entity10 each increased plasma @entity5 by 3-fold and @entity3 concentration slightly but did not significantly change @entity1 . BP did not significantly change. Eight @entity0 discontinued treatment early because of gastrointestinal intolerance to @entity8 (six @entity0 ) and @entity2 with @entity11 (two @entity0 ). In conclusion, each drug increases plasma @entity4 concentration in @entity0 with @entity9 . @entity8 was the most effective but can cause gastrointestinal intolerance and decreased @entity1 . @entity10 and @entity11 have similar but lower efficacies and increase @entity6 depletion. The benefit/risk ratio of each drug should be carefully evaluated for each @entity0 .

title: XXXX , @entity10 , or @entity11 for Treating Hypokalemia in @entity9 .

answer: @entity8


abstract: @entity0 with @entity9 ( @entity9 ), an inherited salt-losing tubulopathy, are usually treated with @entity4 -sparing diuretics or nonsteroidal anti-inflammatory drugs and oral @entity4 and @entity7 supplementations. However, evidence supporting these treatment options is limited to case series studies. We designed an open-label, randomized, crossover study with blind end point evaluation to compare the efficacy and safety of 6-week treatments with one time daily 75 mg slow-release @entity8 , 150 mg @entity11 , or 20 mg @entity10 added to constant @entity4 and @entity7 supplementation in 30 @entity0 with @entity9 (individual participation: 48 weeks). Baseline plasma @entity4 concentration was 2.8  0.4 mmol/L and increased by 0.38 mmol/L (95% confidence interval [95% CI], 0.23 to 0.53; P<0.001) with @entity8 , 0.15 mmol/L (95% CI, 0.02 to 0.29; P=0.03) with @entity11 , and 0.19 mmol/L (95% CI, 0.05 to 0.33; P<0.01) with @entity10 . Fifteen @entity0 became normokalemic: six with @entity8 , three with @entity11 , and six with @entity10 . @entity8 significantly reduced @entity1 and plasma @entity3 concentration. @entity11 and @entity10 each increased plasma @entity5 by 3-fold and @entity3 concentration slightly but did not significantly change @entity1 . BP did not significantly change. Eight @entity0 discontinued treatment early because of gastrointestinal intolerance to @entity8 (six @entity0 ) and @entity2 with @entity11 (two @entity0 ). In conclusion, each drug increases plasma @entity4 concentration in @entity0 with @entity9 . @entity8 was the most effective but can cause gastrointestinal intolerance and decreased @entity1 . @entity10 and @entity11 have similar but lower efficacies and increase @entity6 depletion. The benefit/risk ratio of each drug should be carefully evaluated for each @entity0 .

title: @entity8 , @entity10 , or @entity11 for Treating Hypokalemia in XXXX .

answer: @entity9


abstract: @entity0 with @entity9 ( @entity9 ), an inherited salt-losing tubulopathy, are usually treated with @entity4 -sparing diuretics or nonsteroidal anti-inflammatory drugs and oral @entity4 and @entity7 supplementations. However, evidence supporting these treatment options is limited to case series studies. We designed an open-label, randomized, crossover study with blind end point evaluation to compare the efficacy and safety of 6-week treatments with one time daily 75 mg slow-release @entity8 , 150 mg @entity11 , or 20 mg @entity10 added to constant @entity4 and @entity7 supplementation in 30 @entity0 with @entity9 (individual participation: 48 weeks). Baseline plasma @entity4 concentration was 2.8  0.4 mmol/L and increased by 0.38 mmol/L (95% confidence interval [95% CI], 0.23 to 0.53; P<0.001) with @entity8 , 0.15 mmol/L (95% CI, 0.02 to 0.29; P=0.03) with @entity11 , and 0.19 mmol/L (95% CI, 0.05 to 0.33; P<0.01) with @entity10 . Fifteen @entity0 became normokalemic: six with @entity8 , three with @entity11 , and six with @entity10 . @entity8 significantly reduced @entity1 and plasma @entity3 concentration. @entity11 and @entity10 each increased plasma @entity5 by 3-fold and @entity3 concentration slightly but did not significantly change @entity1 . BP did not significantly change. Eight @entity0 discontinued treatment early because of gastrointestinal intolerance to @entity8 (six @entity0 ) and @entity2 with @entity11 (two @entity0 ). In conclusion, each drug increases plasma @entity4 concentration in @entity0 with @entity9 . @entity8 was the most effective but can cause gastrointestinal intolerance and decreased @entity1 . @entity10 and @entity11 have similar but lower efficacies and increase @entity6 depletion. The benefit/risk ratio of each drug should be carefully evaluated for each @entity0 .

title: @entity8 , XXXX , or @entity11 for Treating Hypokalemia in @entity9 .

answer: @entity10


abstract: @entity0 with @entity9 ( @entity9 ), an inherited salt-losing tubulopathy, are usually treated with @entity4 -sparing diuretics or nonsteroidal anti-inflammatory drugs and oral @entity4 and @entity7 supplementations. However, evidence supporting these treatment options is limited to case series studies. We designed an open-label, randomized, crossover study with blind end point evaluation to compare the efficacy and safety of 6-week treatments with one time daily 75 mg slow-release @entity8 , 150 mg @entity11 , or 20 mg @entity10 added to constant @entity4 and @entity7 supplementation in 30 @entity0 with @entity9 (individual participation: 48 weeks). Baseline plasma @entity4 concentration was 2.8  0.4 mmol/L and increased by 0.38 mmol/L (95% confidence interval [95% CI], 0.23 to 0.53; P<0.001) with @entity8 , 0.15 mmol/L (95% CI, 0.02 to 0.29; P=0.03) with @entity11 , and 0.19 mmol/L (95% CI, 0.05 to 0.33; P<0.01) with @entity10 . Fifteen @entity0 became normokalemic: six with @entity8 , three with @entity11 , and six with @entity10 . @entity8 significantly reduced @entity1 and plasma @entity3 concentration. @entity11 and @entity10 each increased plasma @entity5 by 3-fold and @entity3 concentration slightly but did not significantly change @entity1 . BP did not significantly change. Eight @entity0 discontinued treatment early because of gastrointestinal intolerance to @entity8 (six @entity0 ) and @entity2 with @entity11 (two @entity0 ). In conclusion, each drug increases plasma @entity4 concentration in @entity0 with @entity9 . @entity8 was the most effective but can cause gastrointestinal intolerance and decreased @entity1 . @entity10 and @entity11 have similar but lower efficacies and increase @entity6 depletion. The benefit/risk ratio of each drug should be carefully evaluated for each @entity0 .

title: @entity8 , @entity10 , or XXXX for Treating Hypokalemia in @entity9 .

answer: @entity11


abstract: BACKGROUND AND OBJECTIVE: Because increased @entity2 neurotransmission occurs with most antidepressants, and because antipsychotics cause behavioural supersensitivity to @entity2 , short-term low-dose antipsychotic treatment was tested on @entity1 @entity0 with an expectation of clinical improvement in the supersensitive phase following drug withdrawal. METHOD: This was a randomized, double-blind, placebo-controlled study of 48 @entity0 who met criteria for DSM-IV(  ) Major @entity1 , were in a @entity1 , and had a @entity1 (HAMD) rating of >= 14. Half the @entity0 received 0.25mg oral @entity4 each day for 7 days, after which they received placebo daily for 4 weeks. The other half received placebo throughout the trial. RESULTS: One week after stopping the medication, the HAMD ratings of the drug-treated @entity0 fell by 9.96 points, as compared to a reduction of 8.73 points in the placebo-treated @entity0 , when comparing visits 1 and 4. There was no such difference when comparing visits 2 and 4. The differences were not significant, but indicated a trend. One week after the medication was stopped, the Clinical Global Index fell 1.64  0.18 units for the medication-treated @entity0 , compared to 1.12  0.26 units for the placebo group (P=0.05). The regimen was well tolerated. CONCLUSIONS: Seven days of an ultra-low dose of 0.25mg @entity4 , followed by withdrawal of @entity4 , resulted in clinical @entity1 improvement greater than placebo and significantly @entity3 , consistent with @entity4 -induced behavioural supersensitivity to @entity2 . LIMITATIONS: The sample was small. More @entity0 are needed in a future study.

title: XXXX treatment by withdrawal of short-term low-dose antipsychotic, a proof-of-concept randomized double-blind study.

answer: @entity1


abstract: BACKGROUND: @entity1 are very rare in @entity0 . @entity1 ( @entity1 ) account for the majority of @entity1 in young @entity0 , and @entity2 are a common component of @entity1 in adolescents. CASE PRESENTATION: A 9.8-year-old @entity0 presented with the development of pubic and facial hair over a period of 2 years. He had a growth spurt and examination revealed pubertal staging of G4 P4 A2 with a 6-mls testis on the right and a 4-mls testis on the left. Investigations revealed suppressed gonadotrophins, a @entity3 concentration of 10.3 nmol/l and normal @entity5 and adrenal @entity4 levels. Tumour markers were negative. Following treatment with @entity6 , his height velocity slowed down. At the age of 13.7 years, his treatment was stopped. At the age of 14.8 years, he presented with a grossly enlarged right testis and elevated beta @entity0 chorionic gonadotrophin (>1,400 IU/l). He underwent right orchidectomy and histology revealed an @entity2 with no vascular invasion. Analysis of luteinizing hormone/choriogonadotrophin receptor revealed no mutation. CONCLUSION: We present a case of @entity2 in a @entity0 who had presented 5 years before with features suggestive of gonadotrophin-independent precocious puberty.    2014 S. Karger AG, Basel.

title: Gonadotrophin-independent precocious puberty associated with later diagnosis of XXXX .

answer: @entity2


abstract: OBJECTIVES: Studies have correlated @entity4 ( @entity4 ) with @entity0 , especially respiratory effects. The goal of this study was to measure the impact of @entity4 on the respiratory symptoms and exhaled @entity2 . MATERIAL AND METHODS: The study population consisted of 50 young workers in restaurants serving waterpipes, 48 university students who sit frequently in the university cafeteria where cigarette smoking is allowed and 49 university students spending time in places where smoking is not allowed. Subjects completed questionnaires on socio-demographic characteristics, respiratory symptoms and exposure to @entity4 . Exhaled @entity2 levels were measured. ANOVA and Chi-square tests were used when applicable as well as linear and logistic regression analysis. RESULTS: Exposure to cigarette smoke in university (adjusted odds ratio (ORa) = 6.06) and occupational exposure to waterpipe smoke (ORa = 7.08) were predictors of chronic cough. Being married (ORa = 6.40), living near a heavy traffic road (ORa = 9.49) or near a local power generator (ORa = 7.54) appeared responsible for chronic sputum production. Moreover, predictors of chronic @entity1 were: being male (ORa = 7.81), living near a local power generator (ORa = 5.52) and having a family history of chronic @entity3 (ORa = 17.01). @entity2 levels were augmented by the number of weekly hours of occupational exposure to waterpipe smoke (b = 1.46) and the number of daily hours of exposure to cigarette smoke (b = 1.14). CONCLUSIONS: In summary, young non-smoker subjects demonstrated more chronic cough and elevated @entity2 levels when exposed to @entity4 while the effect of waterpipe was even more evident.

title: XXXX and respiratory symptoms in young adult passive smokers: a pilot study comparing waterpipe to cigarette.

answer: @entity2


abstract: BACKGROUND/OBJECTIVES: Because both, glycemic index (GI) and @entity3 content of the diet increase insulin levels and could thus impair fat oxidation, we hypothesized that refeeding a low GI, moderate- @entity3 diet facilitates weight maintenance. SUBJECTS/METHODS: Healthy @entity0 (n=32, age 26.0  3.9 years; BMI 23.4  2.0   kg/m(2)) followed 1 week of controlled overfeeding, 3 weeks of caloric restriction and 2 weeks of hypercaloric refeeding (+50, -50 and +50% energy requirement) with low vs high GI (41 vs 74) and moderate vs high @entity2 intake (50% vs 65% energy). We measured adaptation of fasting macronutrient oxidation and the capacity to supress fat oxidation during an oral @entity1 tolerance test. Changes in fat mass were measured by quantitative magnetic resonance. RESULTS: During overfeeding, @entity0 gained 1.9  1.2   kg body weight, followed by a weight loss of -6.3  0.6   kg and weight regain of 2.8  1.0   kg. Subjects with 65% @entity2 gained more body weight compared with 50% @entity2 diet (P<0.05) particularly with HGI meals (P<0.01). Refeeding a high-GI diet led to an impaired basal fat oxidation when compared with a low-GI diet (P<0.02), especially at 65% @entity2 intake. Postprandial metabolic flexibility was unaffected by refeeding at 50% @entity2 but clearly impaired by 65% @entity2 diet (P<0.05). Impairment in fasting fat oxidation was associated with regain in fat mass (r=0.43, P<0.05) and body weight (r=0.35; P=0.051). CONCLUSIONS: Both higher GI and higher @entity3 content affect substrate oxidation and thus the regain in body weight in healthy @entity0 . These results argue in favor of a lower glycemic load diet for weight maintenance after weight loss.

title: XXXX intake and glycemic index affect substrate oxidation during a controlled weight cycle in healthy @entity0 .

answer: @entity3


abstract: BACKGROUND/OBJECTIVES: Because both, glycemic index (GI) and @entity3 content of the diet increase insulin levels and could thus impair fat oxidation, we hypothesized that refeeding a low GI, moderate- @entity3 diet facilitates weight maintenance. SUBJECTS/METHODS: Healthy @entity0 (n=32, age 26.0  3.9 years; BMI 23.4  2.0   kg/m(2)) followed 1 week of controlled overfeeding, 3 weeks of caloric restriction and 2 weeks of hypercaloric refeeding (+50, -50 and +50% energy requirement) with low vs high GI (41 vs 74) and moderate vs high @entity2 intake (50% vs 65% energy). We measured adaptation of fasting macronutrient oxidation and the capacity to supress fat oxidation during an oral @entity1 tolerance test. Changes in fat mass were measured by quantitative magnetic resonance. RESULTS: During overfeeding, @entity0 gained 1.9  1.2   kg body weight, followed by a weight loss of -6.3  0.6   kg and weight regain of 2.8  1.0   kg. Subjects with 65% @entity2 gained more body weight compared with 50% @entity2 diet (P<0.05) particularly with HGI meals (P<0.01). Refeeding a high-GI diet led to an impaired basal fat oxidation when compared with a low-GI diet (P<0.02), especially at 65% @entity2 intake. Postprandial metabolic flexibility was unaffected by refeeding at 50% @entity2 but clearly impaired by 65% @entity2 diet (P<0.05). Impairment in fasting fat oxidation was associated with regain in fat mass (r=0.43, P<0.05) and body weight (r=0.35; P=0.051). CONCLUSIONS: Both higher GI and higher @entity3 content affect substrate oxidation and thus the regain in body weight in healthy @entity0 . These results argue in favor of a lower glycemic load diet for weight maintenance after weight loss.

title: @entity3 intake and glycemic index affect substrate oxidation during a controlled weight cycle in healthy XXXX .

answer: @entity0


abstract: OBJECTIVES: To investigate the demographic and neurological features and treatment modalities of neuro- @entity6 ( @entity4 ) in @entity0 , to share our experiences and to summarise the literature. METHODS: We retrospectively reviewed the medical records of @entity6 ( @entity6 ) @entity0 who attended our paediatric rheumatology department between December 2005 and October 2013. Five @entity0 had the diagnosis of @entity4 . Initial neurological presentation, clinical @entity6 presentation, magnetic resonance imaging pictures of those five @entity0 was recorded. RESULTS: A total of 18 @entity0 were diagnosed with @entity6 . Among @entity6 @entity0 five of them were identified with @entity4 (27.8%). The mean age of @entity4 @entity0 at the time of diagnosis was 12.4 years (range 5.5-15 years). The mean follow-up time after the @entity2 was 5.2 years (range 0.5-14). In two cases @entity2 occurred at the same time with the onset of other clinical findings of @entity6 (40%). Both of these @entity0 had parenchymal involvement. Three @entity0 were admitted with @entity1 as the initial neurological symptom. They revealed @entity7 . One of them had @entity3 ( @entity3 ). The other two had normal cranial magnetic resonance imagines. All @entity0 received colchicine and @entity5 , two of them who had parenchymal involvement received also cytotoxic drugs. CONCLUSIONS: This study has shown that neurological symptoms can be the first manifestations of @entity6 in @entity0 . Clinicians should be aware of this possibility and when a @entity0 presents with neurological manifestations, it would be valuable to query the @entity0 for the clinical features of @entity6 .

title: Clinical characteristics of paediatric neuro- XXXX : a single tertiary centre experience.

answer: @entity6


abstract: STUDY QUESTION: What is the risk of complications after @entity2 and what are the factors associated with complications? SUMMARY ANSWER: The cumulative risk of complications after embolization is relatively low even in the long term, but @entity2 location may increase the risk. WHAT IS KNOWN ALREADY: A broad spectrum of complications after @entity1 have been described with widely varying rates. There is uncertainty over the actual risk of complications and the factors associated with this risk. STUDY DESIGN, SIZE, DURATION: This was a prospective cohort study of 288 consecutive @entity0 undergoing @entity1 in the general gynaecology clinic of a university teaching hospital between January 2001 and December 2010. @entity0 /MATERIALS, SETTING, METHODS: Complications occurring after embolization were categorized as major or minor according to the severity of their impact on health, the level of care required and the outcome. Cumulative complication rates were estimated by survival analysis and log-rank tests according to baseline variables. Multivariable Cox proportional hazards analysis was performed to adjust for confounders. MAIN RESULTS AND THE ROLE OF CHANCE: There were 48 @entity0 who experienced a complication at a median of 5 months (95% confidence interval, 4.1-11.4) after embolization. Complications were minor in 38 @entity0 and major in 10 @entity0 . The cumulative overall complication rate was 13% (95% CI, 9.0-17.0) at 6 months, 16% (95% CI, 11.0-20.0) at 1 year, 17% (95% CI, 12.0-22.0) at 3 years and 18% (95% CI, 12.9-22.8) at 5 years. The most frequent complication (19/48, 39.6%) was @entity2 expulsion, which occurred spontaneously in 13 (68.4%) of these cases and required assistance in 6 (31.6%) cases. Eight (2.8%) @entity0 underwent re-intervention, including six hysteroscopic myomectomies, one laparoscopic myomectomy and one hysteroscopic adhesiolysis, as a result of a complication. @entity2 location was the only baseline variable associated with an increased risk for complications [Hazard ratio (HR), 2.28, 95% CI, 1.24-4.18, P = 0.008]. LIMITATIONS, REASONS FOR CAUTION: Our population did not include @entity0 of African descent, who have been reported to be at higher risk of post-procedural complications compared with Causcasian @entity0 . If such @entity0 were involved in the study, higher morbidity rates might have been observed. WIDER IMPLICATIONS OF THE FINDINGS: @entity0 with @entity2 at the time of embolization are more likely to have post-procedural complications. This is important new information for counselling @entity0 contemplating this therapeutic approach. STUDY FUNDING/COMPETING INTERESTS: The authors have no competing interests to declare. The study was not supported by any external grant.

title: Incidence and predictive factors for complications after XXXX .

answer: @entity2


abstract: Raising a @entity0 with @entity1 presents families with exceptional caregiving challenges. Consequently, parents, particularly mothers, evidence unusually high stress levels. Previous research has identified relevant variables that help explain maternal stress: the @entity0 's @entity2 , social support and the sense of coherence (SOC) as a perception of problem. However, there are few longitudinal studies demonstrating how these variables correlate over time. We present a longitudinal study of 21 Spanish mothers of @entity0 with @entity1 ( @entity1 ) at two measurement time points over an interval of 4.5 years. Our aims are to examine the predictive relationships of these variables ( @entity2 , social support and SOC) to stress and to analyse their changes over time. Data were collected through questionnaires. The results of the regression analysis (multiple adjusted R 2= .45,   2 = .82) highlight the predictive values of SOC (adjusted R 2 = .31) and the initial stress levels (   adjusted R 2 = .14) for stress levels 4.5-years later. Our study used t-tests to compare measurements at the two time points; results demonstrate the permanence of stress levels and @entity2 and the effects of reduced social support and increased SOC levels (t(20) = 2.48, p = .02, Cohen's d = .63; t(20) = -4.22, p < .001, Cohen' d = .58). Implications for interventions are discussed.

title: Prediction of stress in mothers of @entity0 with XXXX .

answer: @entity1


abstract: Raising a @entity0 with @entity1 presents families with exceptional caregiving challenges. Consequently, parents, particularly mothers, evidence unusually high stress levels. Previous research has identified relevant variables that help explain maternal stress: the @entity0 's @entity2 , social support and the sense of coherence (SOC) as a perception of problem. However, there are few longitudinal studies demonstrating how these variables correlate over time. We present a longitudinal study of 21 Spanish mothers of @entity0 with @entity1 ( @entity1 ) at two measurement time points over an interval of 4.5 years. Our aims are to examine the predictive relationships of these variables ( @entity2 , social support and SOC) to stress and to analyse their changes over time. Data were collected through questionnaires. The results of the regression analysis (multiple adjusted R 2= .45,   2 = .82) highlight the predictive values of SOC (adjusted R 2 = .31) and the initial stress levels (   adjusted R 2 = .14) for stress levels 4.5-years later. Our study used t-tests to compare measurements at the two time points; results demonstrate the permanence of stress levels and @entity2 and the effects of reduced social support and increased SOC levels (t(20) = 2.48, p = .02, Cohen's d = .63; t(20) = -4.22, p < .001, Cohen' d = .58). Implications for interventions are discussed.

title: Prediction of stress in mothers of XXXX with @entity1 .

answer: @entity0


abstract: Chin tuck has been has been widely used to prevent @entity2 in the @entity0 with @entity3 . This study was performed to investigate the effectiveness and the degree of optimal neck flexion of chin tuck. Ninety-seven @entity0 who showed @entity2 in the videofluoroscopic swallow study (VFSS). @entity0 were grouped into the effective ( @entity0 who showed effect with chin tuck) and ineffective group (those who did not show effect with chin tuck). VFSS was performed in neutral and chin tuck position and findings were compared between the groups. Severity of @entity2 was assessed by the point penetration- @entity2 scale. Duration of @entity1 , history of tracheostomy, and other possible contributing factors were also compared. Neck flexion angle was measured to find appropriate posture in which @entity2 was prevented with chin tuck. Aspiration was reduced or eliminated in only 19 @entity0 (19.6  %) with chin tuck. Oral transit time, pharyngeal delayed time and pharyngeal transit time were significantly shortened in both groups (p  <  0.05), but the difference between the groups was not significant. Female sex and absence of residue in pyriform sinus favored the effect of chin tuck (p  <  0.05). At least 17.5   of neck flexion was required to achieve an effect with chin tuck. The effectiveness of chin tuck was less than anticipated. @entity0 without residue in pyriform sinus were more likely to benefit from chin tuck. Sufficient neck flexion was important in chin tuck to prevent @entity2 .

title: Chin tuck for prevention of XXXX : effectiveness and appropriate posture.

answer: @entity2


abstract: PURPOSE: Uncertainty exists regarding the optimal surveillance imaging strategy following stereotactic body radiation therapy (SBRT) for early-stage @entity4 ( @entity4 ), particularly with respect to timing. We sought to determine how routine use of early (<6 months) posttreatment imaging affects subsequent management. METHODS AND MATERIALS: The records of all @entity0 treated with SBRT between January 2007 and January 2013 for early-stage @entity4 were reviewed. Eligible @entity0 underwent >=  1 early (defined as within 6 months following SBRT) surveillance imaging study. Radiographic findings and subsequent diagnostic or therapeutic interventions were identified. Proportions and exact 95% confidence intervals (CI) with early posttreatment surveillance findings and altered treatment were calculated, and cases were examined descriptively. RESULTS: Sixty-two @entity0 with 67 @entity1 underwent 92 early surveillance imaging studies (86 computed tomographic [CT] and 6 positron emission/CT) at a median of 2.1 months (range, 0.1-5.9 months). New lung nodules were identified in 8 @entity0 (13%), leading to a diagnosis of @entity2 treated with systemic therapy in 2 @entity0 and biopsy proven solitary lung recurrence in 2 @entity0 , both treated successfully with local therapy. Tumor growth meeting Response Evaluation Criteria in @entity3 (RECIST) criteria was identified in 1 @entity0 , who was followed with subsequent radiographic regression. In aggregate, the treatment of 4 @entity0 (6.5%, 95% CI 1.7%-15.2%) was altered by early imaging; 2 (3.2%, 95% CI 0.4%-10.8%) with a potentially curative intervention. No predictors for utility of early surveillance were identified. CONCLUSIONS: Imaging within 6 months following SBRT for early-stage @entity4 resulted in a definitive intervention in approximately 3% of @entity0 . In the era of cost-effective health care, a first scan at 6 months posttreatment may be adequate for most @entity0 . Larger scale prospective studies are needed to address the optimal surveillance regimen following SBRT and to identify @entity0 who may benefit from more aggressive surveillance regimens.

title: Does early posttreatment surveillance imaging affect subsequent management following stereotactic body radiation therapy for early-stage XXXX ?

answer: @entity4


abstract: PURPOSE: We conducted a phase I multicenter trial in na  ve metastatic castrate-resistant @entity3 @entity0 with escalating @entity9 dosages, combined with @entity5 -based chemotherapy. @entity9 is a novel @entity4 receptor agonist with higher antiproliferative effects and a 100-fold lower hypercalcemic activity than @entity7 . EXPERIMENTAL DESIGN: Safety and efficacy were evaluated in groups of three to six @entity0 receiving @entity9 during a 21-day cycle in combination with @entity5 (75 mg/m2 every 3 weeks) and oral @entity2 (5 mg twice a day) up to six cycles. Primary endpoint was dose-limiting @entity1 (DLT) defined as grade 3 @entity6 within the first cycle. Efficacy endpoint was >= 30% @entity8 decline within 3 months. RESULTS: Eight dose levels (40-8,000  g) were evaluated in 54 @entity0 . DLT occurred in two of four @entity0 receiving 8,000  g/day after one and two weeks of @entity9 . Calcemia normalized a few days after interruption of @entity9 . Two other @entity0 reached grade 2, and the dose level was reduced to 4,000  g. After dose reduction, calcemia remained within normal range and grade 1 @entity6 . The maximum tolerated dose was 4,000  g daily. Respectively, 85% and 76% of the @entity0 had >= 30% @entity8 decline within 3 months and >= 50% @entity8 decline at any time during the study. Median time to @entity8 progression was 169 days. CONCLUSION: High antiproliferative daily @entity9 dose has been safely used in combination with @entity5 and shows encouraging @entity8 response (>= 30% @entity8 response: 85%; >= 50% @entity8 response: 76%). A randomized phase II study is planned.

title: Phase I safety and pharmacodynamic of @entity9 , a novel VDR agonist with XXXX in metastatic castration-resistant @entity3 @entity0 .

answer: @entity5


abstract: PURPOSE: We conducted a phase I multicenter trial in na  ve metastatic castrate-resistant @entity3 @entity0 with escalating @entity9 dosages, combined with @entity5 -based chemotherapy. @entity9 is a novel @entity4 receptor agonist with higher antiproliferative effects and a 100-fold lower hypercalcemic activity than @entity7 . EXPERIMENTAL DESIGN: Safety and efficacy were evaluated in groups of three to six @entity0 receiving @entity9 during a 21-day cycle in combination with @entity5 (75 mg/m2 every 3 weeks) and oral @entity2 (5 mg twice a day) up to six cycles. Primary endpoint was dose-limiting @entity1 (DLT) defined as grade 3 @entity6 within the first cycle. Efficacy endpoint was >= 30% @entity8 decline within 3 months. RESULTS: Eight dose levels (40-8,000  g) were evaluated in 54 @entity0 . DLT occurred in two of four @entity0 receiving 8,000  g/day after one and two weeks of @entity9 . Calcemia normalized a few days after interruption of @entity9 . Two other @entity0 reached grade 2, and the dose level was reduced to 4,000  g. After dose reduction, calcemia remained within normal range and grade 1 @entity6 . The maximum tolerated dose was 4,000  g daily. Respectively, 85% and 76% of the @entity0 had >= 30% @entity8 decline within 3 months and >= 50% @entity8 decline at any time during the study. Median time to @entity8 progression was 169 days. CONCLUSION: High antiproliferative daily @entity9 dose has been safely used in combination with @entity5 and shows encouraging @entity8 response (>= 30% @entity8 response: 85%; >= 50% @entity8 response: 76%). A randomized phase II study is planned.

title: Phase I safety and pharmacodynamic of @entity9 , a novel VDR agonist with @entity5 in metastatic castration-resistant XXXX @entity0 .

answer: @entity3


abstract: PURPOSE: We conducted a phase I multicenter trial in na  ve metastatic castrate-resistant @entity3 @entity0 with escalating @entity9 dosages, combined with @entity5 -based chemotherapy. @entity9 is a novel @entity4 receptor agonist with higher antiproliferative effects and a 100-fold lower hypercalcemic activity than @entity7 . EXPERIMENTAL DESIGN: Safety and efficacy were evaluated in groups of three to six @entity0 receiving @entity9 during a 21-day cycle in combination with @entity5 (75 mg/m2 every 3 weeks) and oral @entity2 (5 mg twice a day) up to six cycles. Primary endpoint was dose-limiting @entity1 (DLT) defined as grade 3 @entity6 within the first cycle. Efficacy endpoint was >= 30% @entity8 decline within 3 months. RESULTS: Eight dose levels (40-8,000  g) were evaluated in 54 @entity0 . DLT occurred in two of four @entity0 receiving 8,000  g/day after one and two weeks of @entity9 . Calcemia normalized a few days after interruption of @entity9 . Two other @entity0 reached grade 2, and the dose level was reduced to 4,000  g. After dose reduction, calcemia remained within normal range and grade 1 @entity6 . The maximum tolerated dose was 4,000  g daily. Respectively, 85% and 76% of the @entity0 had >= 30% @entity8 decline within 3 months and >= 50% @entity8 decline at any time during the study. Median time to @entity8 progression was 169 days. CONCLUSION: High antiproliferative daily @entity9 dose has been safely used in combination with @entity5 and shows encouraging @entity8 response (>= 30% @entity8 response: 85%; >= 50% @entity8 response: 76%). A randomized phase II study is planned.

title: Phase I safety and pharmacodynamic of @entity9 , a novel VDR agonist with @entity5 in metastatic castration-resistant @entity3 XXXX .

answer: @entity0


abstract: PURPOSE: We conducted a phase I multicenter trial in na  ve metastatic castrate-resistant @entity3 @entity0 with escalating @entity9 dosages, combined with @entity5 -based chemotherapy. @entity9 is a novel @entity4 receptor agonist with higher antiproliferative effects and a 100-fold lower hypercalcemic activity than @entity7 . EXPERIMENTAL DESIGN: Safety and efficacy were evaluated in groups of three to six @entity0 receiving @entity9 during a 21-day cycle in combination with @entity5 (75 mg/m2 every 3 weeks) and oral @entity2 (5 mg twice a day) up to six cycles. Primary endpoint was dose-limiting @entity1 (DLT) defined as grade 3 @entity6 within the first cycle. Efficacy endpoint was >= 30% @entity8 decline within 3 months. RESULTS: Eight dose levels (40-8,000  g) were evaluated in 54 @entity0 . DLT occurred in two of four @entity0 receiving 8,000  g/day after one and two weeks of @entity9 . Calcemia normalized a few days after interruption of @entity9 . Two other @entity0 reached grade 2, and the dose level was reduced to 4,000  g. After dose reduction, calcemia remained within normal range and grade 1 @entity6 . The maximum tolerated dose was 4,000  g daily. Respectively, 85% and 76% of the @entity0 had >= 30% @entity8 decline within 3 months and >= 50% @entity8 decline at any time during the study. Median time to @entity8 progression was 169 days. CONCLUSION: High antiproliferative daily @entity9 dose has been safely used in combination with @entity5 and shows encouraging @entity8 response (>= 30% @entity8 response: 85%; >= 50% @entity8 response: 76%). A randomized phase II study is planned.

title: Phase I safety and pharmacodynamic of XXXX , a novel VDR agonist with @entity5 in metastatic castration-resistant @entity3 @entity0 .

answer: @entity9


abstract: BACKGROUND AND PURPOSE: The pancreas is located almost entirely within the treatment area for radiotherapy of @entity2 . The aim of this study was to analyze radiation-induced @entity1 . MATERIAL AND METHODS: The study included 127 @entity2 @entity0 , who underwent preoperative or postoperative chemoradiotherapy. A total dose of 45Gy was given in 25 fractions. Concurrent chemotherapy was @entity5 -based. Lipase and a-amylase were assayed before, during and after treatment. RESULTS: Lipase and @entity4 were found in 48.2% and 19.7% of @entity0 , respectively. In the univariant analysis, age and pretreatment a-amylase and lipase activities influenced on risk of @entity1 (p<0.05). Younger @entity0 (<65years) had a lower risk of hypoamylasemia than older @entity0 . The probability of insufficiency was lower than 0.2 for @entity0 with pretreatment a-amylase and lipase activities above 50U/L and 55U/L, respectively. The multivariate analyses of the time to hypolipasemia showed that only pretreatment lipase activity was significant. CONCLUSIONS: @entity2 @entity0 have an increased risk of exocrine @entity6 after chemoradiotherapy. Thus, the pancreas should be regarded as an OAR. Measuring lipase activity should be the standard for assessing radiation-induced @entity3 .

title: Radiation-induced @entity1 after chemoradiotherapy for XXXX .

answer: @entity2


abstract: BACKGROUND AND PURPOSE: The pancreas is located almost entirely within the treatment area for radiotherapy of @entity2 . The aim of this study was to analyze radiation-induced @entity1 . MATERIAL AND METHODS: The study included 127 @entity2 @entity0 , who underwent preoperative or postoperative chemoradiotherapy. A total dose of 45Gy was given in 25 fractions. Concurrent chemotherapy was @entity5 -based. Lipase and a-amylase were assayed before, during and after treatment. RESULTS: Lipase and @entity4 were found in 48.2% and 19.7% of @entity0 , respectively. In the univariant analysis, age and pretreatment a-amylase and lipase activities influenced on risk of @entity1 (p<0.05). Younger @entity0 (<65years) had a lower risk of hypoamylasemia than older @entity0 . The probability of insufficiency was lower than 0.2 for @entity0 with pretreatment a-amylase and lipase activities above 50U/L and 55U/L, respectively. The multivariate analyses of the time to hypolipasemia showed that only pretreatment lipase activity was significant. CONCLUSIONS: @entity2 @entity0 have an increased risk of exocrine @entity6 after chemoradiotherapy. Thus, the pancreas should be regarded as an OAR. Measuring lipase activity should be the standard for assessing radiation-induced @entity3 .

title: Radiation-induced XXXX after chemoradiotherapy for @entity2 .

answer: @entity1


abstract: OBJECTIVE: We sought to determine the factors associated with survival after recurrence of @entity2 ( @entity2 ) after resection and the outcome of our prospectively applied treatment protocol. BACKGROUND: Very little is known about the prognosis of @entity2 that recurs after resection and the outcomes associated with treatments applied to recurrent @entity1 . METHODS: A total of 661 @entity2 @entity0 undergoing resection from January 1988 to January 2011 were reviewed to identify those with recurrence. Single recurrences with preserved liver function, and no portal @entity3 were treated with resection. @entity0 with multiple @entity1 or poor liver function and no major comorbidities were listed for transplantation. @entity0 with up to 3 @entity1 , each 4 cm or smaller, and not eligible for transplantation, received ablation. @entity0 not eligible for ablation received embolization. Other treatments such as systemic therapy and radiation were used in remaining @entity0 , but not in a systematic manner. RESULTS: Recurrent @entity2 developed in 356 (54%) @entity0 at a median time of 22 months from primary resection. Median survival from time of recurrence to @entity5 was 21 months. Variables independently associated with survival from recurrence included time from primary resection to recurrence, @entity4 more than 100 ng/mL at recurrence, @entity1 larger than 3 cm, BCLC stage at recurrence, and type of treatment rendered for the recurrence. All variables except treatment modality were significantly correlated with characteristics of the original @entity1 . CONCLUSIONS: Most of the variables associated with outcome after recurrence are linked to the @entity1 at initial presentation. Nevertheless, meaningful survival can be achieved with appropriate treatment of recurrent @entity1 .

title: Recurrence of XXXX after resection: patterns, treatments, and prognosis.

answer: @entity2


abstract: OBJECTIVE: The aim of the study was to evaluate the ability of a data-fusion @entity0 status index (PSI) to detect @entity0 deterioration in the @entity1 ( @entity1 ) in comparison with track-and-trigger (T_T). MATERIALS AND METHODS: A single-centre observational cohort study was conducted in a medium-sized teaching hospital @entity1 . Vital sign data and any documented T_T scores ( @entity3 ) were collected from adults attending the resuscitation room, majors or observation ward. For each set of vital signs, we retrospectively calculated T_T (eT_T). PSI was calculated retrospectively from the continuous vital sign data using a statistical model of normality. Clinical notes were examined to identify 'escalation' events, and the numbers of these escalations identified by @entity3 , eT_T and PSI were retrospectively calculated. RESULTS: Data from 472 @entity0 episodes were examined. A total of 20 @entity0 had PSI data at the time of an escalation related to @entity2 that occurred during their @entity1 stay (vs. on arrival). Only four @entity0 events were detected at the time by @entity3 . In all, 17 were detected retrospectively by eT_T and 15 by PSI. PSI had a calculated false-alert rate of 1.13   alerts/bed-day. CONCLUSION: Electronic data capture offers opportunities for increased detection of deteriorating @entity0 in a busy clinical environment compared with paper charts. Sample size in this study is insufficient to determine which electronic method (eT_T or PSI) offers superior detection of the need for escalation.

title: Analysis of a data-fusion system for continuous vital sign monitoring in an XXXX .

answer: @entity1


abstract: BACKGROUND: The MISSED score was derived and validated in @entity3 ( @entity3 ) @entity0 with @entity2 who were admitted to the ICU. This score has now been refined and simplified. The independent variables associated with mortality are age at least 65 years, serum albumin 27   g/l or less, and an international normalized ratio at least 1.3. The simplified MISSED score ranges from 0 to 3 depending on the number of variables present. OBJECTIVE: The primary objective is to validate the simplified MISSED score for predicting all-cause mortality in the @entity3 population admitted with @entity2 . The secondary end-point is to validate the risk stratification for ICU admission. METHODS: This is a pragmatic retrospective study of prospectively collected data. @entity3 @entity0 admitted with a diagnosis of @entity2 in the year 2012 were studied. Those on @entity4 were excluded. The simplified MISSED score was calculated for each @entity0 . The test characteristics for mortality of the simplified MISSED score and the odds ratios of the high-risk groups for the secondary end-point were calculated. RESULTS: In total, 674 @entity0 , including 65 @entity1 , were studied. The area under the curve for the simplified MISSED score was 0.74 [95% confidence interval (CI) 0.70-0.77; P<0.0001]. The test characteristics for mortality were as follows: sensitivity 93.9% (95% CI 85-98.3), specificity 37.9% (95% CI 34.1-41.9), positive predictive value 13.9% (95% CI 10.8-17.5), and negative predictive value 98.3% (95% CI 95.7-99.5). The odds ratio for mortality for a score 2 or more was 5.01 (95% CI 2.93-8.57; P<0.0001), and that for ICU admission was 3.00 (95% CI 1.70-5.28; P=0.0001). CONCLUSION: The simplified MISSED score could be used to risk stratify septic @entity0 in the @entity3 .

title: Internal XXXX validation of the simplified MISSED score.

answer: @entity3


abstract: BACKGROUND: Forcipomyia taiwana ( @entity6 ) is the most prevalent allergenic biting insect in Taiwan and 60% of the exposed subjects develop @entity2 . Subjects with insect @entity4 frequently limit their outdoor activities to avoid the annoyingly intense @entity2 , leading to significant worsening of their quality of life. Allergen specific immunotherapy is the only known therapy that provides long-term host immune tolerance to the allergen, but is time-consuming and cumbersome. This study tested if the For t 2 DNA vaccine can prevent @entity2 in For t 2 sensitized @entity0 . MATERIALS AND METHODS: Two consecutive shots of For t 2 DNA vaccine were given to @entity0 with a 7-day interval before sensitization with recombinant For t 2 proteins, using the two-step sensitization protocol reported previously. RESULTS: The For t 2 DNA vaccine at 50  g prevented the production of For t 2-specific IgE (p<0.05), as well as midge-allergen challenge induced scratch bouts, midge-allergen induced @entity5 and @entity3 production from splenocytes, and inflammatory cell infiltrations in the lesions 48 hours after intra-dermal challenge. CONCLUSIONS: This study is the first to demonstrate that DNA vaccine encoding midge allergen is effective in preventing @entity1 induced by @entity6 . Immunotherapy using For t 2 DNA vaccine can protect @entity0 from being sensitized by midge allergen and may be a promising treatment for @entity6 @entity4 in the future. This article is protected by copyright. All rights reserved.

title: For t 2 DNA Vaccine Prevents Forcipomyia taiwana ( XXXX ) Allergy in a @entity0 Model.

answer: @entity6


abstract: BACKGROUND: Forcipomyia taiwana ( @entity6 ) is the most prevalent allergenic biting insect in Taiwan and 60% of the exposed subjects develop @entity2 . Subjects with insect @entity4 frequently limit their outdoor activities to avoid the annoyingly intense @entity2 , leading to significant worsening of their quality of life. Allergen specific immunotherapy is the only known therapy that provides long-term host immune tolerance to the allergen, but is time-consuming and cumbersome. This study tested if the For t 2 DNA vaccine can prevent @entity2 in For t 2 sensitized @entity0 . MATERIALS AND METHODS: Two consecutive shots of For t 2 DNA vaccine were given to @entity0 with a 7-day interval before sensitization with recombinant For t 2 proteins, using the two-step sensitization protocol reported previously. RESULTS: The For t 2 DNA vaccine at 50  g prevented the production of For t 2-specific IgE (p<0.05), as well as midge-allergen challenge induced scratch bouts, midge-allergen induced @entity5 and @entity3 production from splenocytes, and inflammatory cell infiltrations in the lesions 48 hours after intra-dermal challenge. CONCLUSIONS: This study is the first to demonstrate that DNA vaccine encoding midge allergen is effective in preventing @entity1 induced by @entity6 . Immunotherapy using For t 2 DNA vaccine can protect @entity0 from being sensitized by midge allergen and may be a promising treatment for @entity6 @entity4 in the future. This article is protected by copyright. All rights reserved.

title: For t 2 DNA Vaccine Prevents Forcipomyia taiwana ( @entity6 ) Allergy in a XXXX Model.

answer: @entity0


abstract: INTRODUCTION: Weight loss and physical activity achieved through the @entity1 Prevention Program (DPP) have been shown to reduce type 2 @entity1 risk among individuals with @entity3 . The New York State Young @entity0 's Christian Association (YMCA) delivered the 16-week evidence-based model at 14 YMCAs. A mixed methods process and outcomes evaluation was conducted. METHODS: Most @entity0 were referred by clinicians and were encouraged to achieve 5% to 7% @entity2 . @entity0 were weighed weekly; additional data were gathered from @entity0 surveys and focus groups and staff surveys and interviews. RESULTS: @entity0 (N = 254) lost a mean of 9 pounds (P < .001), or 4.2% of body weight, by program completion; 40% achieved 5% or more @entity2 and 25% achieved 7% or more @entity2 . Ten months after baseline, 61% of @entity0 reported 5% or more @entity2 and 48% reported 7% or more @entity2 . In multivariate models, @entity2 was negatively associated with black race (16 weeks: adjusted odds ratio [AOR], 0.190, P = .002; 10 months: AOR, 0.244, P = .005) and positively associated with attendance (16 weeks: AOR, 18.699, P < .001; 10 months: AOR, 2.808, P = .024). @entity0 reported improvements in health and lifestyle changes after program completion. Factors contributing to program success included coaches who motivated @entity0 , the group setting, curriculum, and program duration. However, sociodemographic diversity was limited. CONCLUSION: Outcomes demonstrate the potential for effectively implementing the DPP in community-based settings. Findings also suggest the need for replications among a broader population.

title: Implementation and outcomes of the New York State YMCA XXXX prevention program: a multisite community-based translation, 2010-2012.

answer: @entity1


abstract: INTRODUCTION: @entity7 has a high mortality and morbidity in @entity0 . Aggressive @entity4 , early referral, secondary transport and vaccination are potential factors with impact in reducing its mortality. Objectives were to characterize @entity0 admitted to intensive care due to @entity7 , to evaluate their prognostic scores and mortality. MATERIAL AND METHODS: Observational study, with retrospective data collection. Two periods were created according to the year of admission (A: 2000-2005 and B: 2006-2011). Prognostic parameters, organ failure and mortality rates were compared in these groups. RESULTS: 70 @entity0 were admitted with @entity7 . When compared with other causes of admission, a decrease in the number of admissions due to @entity7 was observed (period A: 3.4%; period B: 1.5%; p = 0.001). The presence of @entity1 was 41% in period A and 29% in period B (p = 0.461). Rapidly progressive @entity5 occurred in 78% in period A and 50% in period B (p = 0.032). @entity0 from period A had @entity3 (80%), disseminated @entity6 (76%) and @entity2 (22%) more frequently than @entity0 from period B (29%, 29%, 0%; p < 0.05). Mortality was 26% in period A and 0% in period B (p = 0.006) and standardized mortality by PRISM was 1.3 and 0 in period A and B respectively. DISCUSSION: The decrease in the number of admissions due to @entity7 can be explained by the introduction of anti-meningococcal C vaccine in 2006. Mortality decline can be possibly explained by an improvement in the initial @entity0 stabilization and to secondary transport. CONCLUSION: A decrease in the number of admissions due to @entity7 and in mortality was observed.

title: [ XXXX admissions in a paediatric intensive care unit].

answer: @entity7


abstract: BACKGROUND: @entity2 remains the most frequent complication associated with cryoballoon-based pulmonary vein (PV) isolation. We sought to characterize our experience using a novel monitoring technique for the prevention of @entity2 . METHODS AND RESULTS: Two hundred consecutive cryoballoon-based PV isolation procedures between October 2010 and October 2013 were studied. In addition to standard abdominal palpation during right phrenic nerve pacing from the superior vena cava, all @entity0 underwent diaphragmatic electromyographic monitoring using surface electrodes. Cryoablation was terminated on any perceived reduction in diaphragmatic motion or a 30% decrease in the compound motor action potential (CMAP). During right-sided ablation, a >= 30% reduction in CMAP amplitude occurred in 49 @entity0 (24.5%). Diaphragmatic motion decreased in 30 of 49 @entity0 and was preceded by a 30% reduction in CMAP amplitude in all. In 82% of cases, this reduction in CMAP amplitude occurred during right superior PV isolation. The baseline CMAP amplitude was 946.5  609.2 mV and decreased by 13.8  13.8% at the end of application. This decrease was more marked in the 33 PVs with a reduction in diaphragmatic motion than in those without (40.9  15.3% versus 11.3  10.5%; P<0.001). In 3 cases, @entity2 persisted beyond the end of the procedure, with all cases recovering within 6 months. Despite the shortened application all veins were isolated. At repeat procedure the right-sided PVs reconnected less frequently than the left-sided PVs in those with @entity2 . CONCLUSIONS: Electromyographic phrenic nerve monitoring using the surface CMAP is reliable, easy to perform, and offers an early warning to impending @entity1 .

title: Clinical experience with a novel electromyographic approach to preventing XXXX during cryoballoon ablation in atrial fibrillation.

answer: @entity1


abstract: BACKGROUND: Previous Canadian cost-effectiveness analyses in @entity0 based on the EQ-5D-3L (EuroQoL, Rotterdam, Netherlands) have commonly used U.K. or U.S. tariffs because the Canadian equivalent only just recently became available. The implications of using non-Canadian tariffs to inform decision-making are unclear. We aimed to reevaluate an earlier cost-effectiveness analysis of therapies for metastatic @entity3 (originally performed using U.S. tariffs) with tariffs from Canada and various other countries to determine the impact of using non-country-specific tariffs. METHODS: We used tariffs from Canada, the United States, the United Kingdom, Denmark, France, Germany, Japan, the Netherlands, and Spain to derive EQ-5D-3L utilities for the 10 health states in the @entity3 model. Quality-adjusted life years (qalys) and @entity4 ( @entity4 ) were generated, and probabilistic sensitivity analyses (psas) were performed. RESULTS: Canadian utilities are generally lower than the corresponding U.S. utilities and higher than those for the United Kingdom. Compared with the Canadian-valued scenarios, U.S. and U.K. estimates were statistically different for 3 and 9 scenarios respectively. Overall, 35% of the non-Canadian utilities (28 of 80) were significantly different, clinically, from the Canadian values. Canadian qalys were 6% lower than those for the United States and 6% higher than those for the United Kingdom. When comparing the qalys of each treatment with those of @entity1 alone, the average percent change was +6.8% for a U.S. scenario and -7.5% for a U.K. scenario compared with a Canadian scenario. Consequently, Canadian @entity4 were approximately 5.4% greater than those for the United States and 8.6% lower than those for the United Kingdom. Based on the psas and compared with the Canadian threshold value, the minimum willingness-to-pay threshold at which the combination chemotherapy regimen of @entity1 - @entity2 is the most cost-effective is  5,239 less than in the United States and  11,986 more than in the United Kingdom. CONCLUSIONS: The use of non-country-specific tariffs leads to significant differences in the derived utilities, @entity4 , and psa results. Past Canadian EQ-5D-3L-based cost-effectiveness analyses and related funding decisions might need to be re-visited using Canadian tariffs.

title: Impact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic XXXX .

answer: @entity3


abstract: BACKGROUND: @entity4 , daily hives that last >6 weeks, can be resistant to antihistamines, even when higher than conventional doses are used. Other pharmacologic agents have been associated with inconsistent benefit. OBJECTIVE: We examined the relationship of clinical characteristics and the presence of autoimmune antibodies to @entity5 resistance in @entity0 . We further examined the efficacy and safety of @entity2 in @entity0 whose @entity1 was resistant to @entity5 . METHODS: @entity0 referred to the pediatric @entity3 and pulmonary specialty clinic at the University of Iowa @entity0 's Hospital and diagnosed as having chronic idiopathic @entity1 were identified during the period from August 2008 to July 2013. A retrospective examination of treatment and outcome was performed. RESULTS: Forty-six @entity0 , 26 female @entity0 and 20 male @entity0 , with chronic idiopathic @entity1 were identified. The ages of 16 @entity0 who were @entity5 resistant ranged from 9 to 18 years (median, 12.5 years). Those @entity0 who were @entity5 responsive had a median age of 6 years, significantly lower than those who were @entity5 resistant (P  = .0001). There was no significant association between autoimmune antibodies and @entity5 resistance. All the @entity0 who were @entity5 resistant were treated with @entity2 ; all experienced complete resolution of @entity1 at times that ranged from 2 days to 3 months (median, 7 days). Relapses responsive to repeated @entity2 occurred in 5 of the @entity0 after 1 week to 15 months (median, 6 months). Adverse effects were not seen in these @entity0 . CONCLUSION: Our data were consistent with efficacy and safety of @entity2 for chronic @entity1 in @entity0 when even high doses of antihistamines are ineffective.

title: Treatment of chronic @entity1 in children with antihistamines and XXXX .

answer: @entity2


abstract: BACKGROUND: @entity4 , daily hives that last >6 weeks, can be resistant to antihistamines, even when higher than conventional doses are used. Other pharmacologic agents have been associated with inconsistent benefit. OBJECTIVE: We examined the relationship of clinical characteristics and the presence of autoimmune antibodies to @entity5 resistance in @entity0 . We further examined the efficacy and safety of @entity2 in @entity0 whose @entity1 was resistant to @entity5 . METHODS: @entity0 referred to the pediatric @entity3 and pulmonary specialty clinic at the University of Iowa @entity0 's Hospital and diagnosed as having chronic idiopathic @entity1 were identified during the period from August 2008 to July 2013. A retrospective examination of treatment and outcome was performed. RESULTS: Forty-six @entity0 , 26 female @entity0 and 20 male @entity0 , with chronic idiopathic @entity1 were identified. The ages of 16 @entity0 who were @entity5 resistant ranged from 9 to 18 years (median, 12.5 years). Those @entity0 who were @entity5 responsive had a median age of 6 years, significantly lower than those who were @entity5 resistant (P  = .0001). There was no significant association between autoimmune antibodies and @entity5 resistance. All the @entity0 who were @entity5 resistant were treated with @entity2 ; all experienced complete resolution of @entity1 at times that ranged from 2 days to 3 months (median, 7 days). Relapses responsive to repeated @entity2 occurred in 5 of the @entity0 after 1 week to 15 months (median, 6 months). Adverse effects were not seen in these @entity0 . CONCLUSION: Our data were consistent with efficacy and safety of @entity2 for chronic @entity1 in @entity0 when even high doses of antihistamines are ineffective.

title: Treatment of chronic XXXX in children with antihistamines and @entity2 .

answer: @entity1


abstract: OBJECTIVES: The neutrophil-lymphocyte ratio (NLR) is an indicator of the systemic inflammatory response. An increased pretreatment NLR has been associated with adverse outcomes in other @entity2 , but its role in localized (M0) @entity5 ( @entity5 ) remains unclear. As such, we evaluated the ability of preoperative NLR to predict oncologic outcomes in @entity0 with M0 @entity5 undergoing radical nephrectomy (RN). METHODS AND MATERIALS: From 1995 to 2008, 952 @entity0 underwent RN for M0 @entity5 . Of these, 827 (87%) had pretreatment NLR collected within 90 days before RN. @entity1 -free, @entity2 -specific, and overall survival was estimated using the Kaplan-Meier method and compared using the log-rank test. Multivariate models were used to analyze the association of NLR with clinicopathologic outcomes. RESULTS: At a median follow-up of 9.3 years, 302, 233, and 436 @entity0 had distant @entity1 , @entity4 from @entity5 , and all-cause mortality, respectively. Higher NLR was associated with larger @entity2 size, higher nuclear grade, @entity3 , and sarcomatoid differentiation (all, P<0.001). A NLR>= 4.0 was significantly associated with worse 5-year @entity2 -specific (66% vs. 85%) and overall survival (66% vs. 85%). Finally, after controlling for clinicopathologic features, NLR remained independently associated with risks of @entity4 from @entity5 and all-cause mortality (hazard ratio for 1-unit increase: 1.02, P< 0.01). CONCLUSIONS: Our results suggest that NLR is independently associated with increased risks of @entity2 -specific and all-cause mortality among @entity0 with M0 @entity5 undergoing RN. Accordingly, NLR, an easily obtained marker of biologically aggressive @entity5 , may be useful in preoperative @entity0 risk stratification.

title: Preoperative neutrophil-lymphocyte ratio predicts XXXX among @entity0 with localized clear cell renal carcinoma undergoing nephrectomy.

answer: @entity4


abstract: OBJECTIVES: The neutrophil-lymphocyte ratio (NLR) is an indicator of the systemic inflammatory response. An increased pretreatment NLR has been associated with adverse outcomes in other @entity2 , but its role in localized (M0) @entity5 ( @entity5 ) remains unclear. As such, we evaluated the ability of preoperative NLR to predict oncologic outcomes in @entity0 with M0 @entity5 undergoing radical nephrectomy (RN). METHODS AND MATERIALS: From 1995 to 2008, 952 @entity0 underwent RN for M0 @entity5 . Of these, 827 (87%) had pretreatment NLR collected within 90 days before RN. @entity1 -free, @entity2 -specific, and overall survival was estimated using the Kaplan-Meier method and compared using the log-rank test. Multivariate models were used to analyze the association of NLR with clinicopathologic outcomes. RESULTS: At a median follow-up of 9.3 years, 302, 233, and 436 @entity0 had distant @entity1 , @entity4 from @entity5 , and all-cause mortality, respectively. Higher NLR was associated with larger @entity2 size, higher nuclear grade, @entity3 , and sarcomatoid differentiation (all, P<0.001). A NLR>= 4.0 was significantly associated with worse 5-year @entity2 -specific (66% vs. 85%) and overall survival (66% vs. 85%). Finally, after controlling for clinicopathologic features, NLR remained independently associated with risks of @entity4 from @entity5 and all-cause mortality (hazard ratio for 1-unit increase: 1.02, P< 0.01). CONCLUSIONS: Our results suggest that NLR is independently associated with increased risks of @entity2 -specific and all-cause mortality among @entity0 with M0 @entity5 undergoing RN. Accordingly, NLR, an easily obtained marker of biologically aggressive @entity5 , may be useful in preoperative @entity0 risk stratification.

title: Preoperative neutrophil-lymphocyte ratio predicts @entity4 among XXXX with localized clear cell renal carcinoma undergoing nephrectomy.

answer: @entity0


abstract: A challenging aspect of @entity2 control in @entity1 populations is the design and implementation of effective surveillance and monitoring programmes, both for early warning, and to determine the ongoing epidemiological situation in an infected population. Testing blood samples requires invasive sampling strategies like hunting or capture of @entity1 . Besides being biased towards healthy animals, such strategies are also linked to further spread of the virus. Non-invasive sampling strategies would increase the reliability of surveillance of @entity2 in @entity1 populations, without the negative side effects. This study evaluates the potential of faeces and tissue samples as a basis for non-invasive sampling strategies for @entity2 in @entity1 . In the acute phase (0-21 days after @entity0 ), in comparison with virus detection in blood, virus can be detected in faeces 50-80% of the time. This percentage decreases to below 10% for the subacute/chronic phase. @entity2 DNA is quite stable in faeces. Half-lives range from more than 2 years at temperature up to 12  C, to roughly 15 days at temperatures of 30  C. In tissue samples, stored at 20  C, half-lives mostly range from 1.7 to 7.4 days. The sample of preference is the spleen, where the highest titres and highest half-life of @entity2 DNA are observed. The level and duration of excretion of @entity2 in the faeces, combined with the stability of the DNA, suggest that sampling of faeces could be the basis for a non-invasive sampling strategy to monitor @entity2 in @entity1 .

title: Suitability of faeces and tissue samples as a basis for non-invasive sampling for African swine fever in XXXX .

answer: @entity1


abstract: BACKGROUND: @entity5 establishes @entity6 in @entity8 ( @entity8 ) @entity0 . As the disease progresses, @entity5 pathoadaptive variants are distinguished from the initially acquired strain. However, the genetic basis and the biology of host-bacteria interactions leading to a persistent lifestyle of @entity5 are not understood. As a model system to study long term and persistent @entity8 , the @entity5 RP73, isolated 16.9  years after the onset of airways colonization from a @entity8 @entity0 , was investigated. Comparisons with strains RP1, isolated at the onset of the colonization, and clonal RP45, isolated 7  years before RP73 were carried out to better characterize genomic evolution of @entity5 in the context of @entity8 pathogenicity. RESULTS: Virulence assessments in disease animal model, genome sequencing and comparative genomics analysis were performed for clinical RP73, RP45, RP1 and prototype strains. In @entity1 model, RP73 showed lower lethality and a remarkable capability of long-term persistence in chronic airways infection when compared to other strains. Pathological analysis of @entity1 lungs confirmed advanced chronic @entity4 , @entity2 and mucus @entity7 . Genomic analysis predicted twelve genomic islands in the RP73 genome, some of which distinguished RP73 from other prototype strains and corresponded to regions of genome plasticity. Further, comparative genomic analyses with sequential RP isolates showed signatures of pathoadaptive mutations in virulence factors potentially linked to the development of @entity3 in @entity8 . CONCLUSIONS: The genome plasticity of @entity5 particularly in the RP73 strain strongly indicated that these alterations may form the genetic basis defining host-bacteria interactions leading to a persistent lifestyle in @entity0 lungs.

title: Comparative genomics and biological characterization of sequential XXXX isolates from persistent airways infection.

answer: @entity5


abstract: BACKGROUND: Maintaining optimal fluid balance is essential in haemodialysis (HD) @entity0 but clinical evaluation remains problematic. Other technologies such as bioimpedance are emerging as valuable adjuncts. This study was undertaken to explore the potential utility of the natriuretic peptides - atrial natriuretic peptide (ANP) and @entity2 ( @entity2 ) in the assessment of fluid status and cardiovascular risk in this setting. METHODS: This was a cross-sectional study carried out in an unselected cohort of 170 prevalent HD @entity0 . Volume status was assessed by clinical parameters - the presence or absence of peripheral @entity1 , raised jugular venous pressure and basal lung crepitations; by extracellular fluid volume (ECFV) status determined by whole body bioimpedance; and by serum levels of @entity2 and ANP (pre- and post -dialysis). The relationships of ANP and @entity2 levels to clinical and bioimpedance parameters of volume status was determined. @entity0 were followed up for 5  years to assess the relationship of natriuretic peptide levels to mortality. RESULTS: Bioimpedance estimates of ECFV expansion (>105  % of ideal ECFV) was present in 52  % of @entity0 pre-dialysis. A significant proportion (21  %) of pre-dialysis @entity0 had a depleted ECFV (<95  % of ideal ECFV) pre-dialysis. The situation was reversed post-dialysis. A raised JVP >3  cm was the most reliable clinical sign of ECFV expansion inferred from bioimpedance measurements and natriuretic peptide levels. The vast majority of @entity0 with this sign also had lung crepitations or peripheral @entity1 or both. @entity2 was a stronger predictor of ECFV expansion than either pre- or post-dialysis ANP. @entity2 was also a stronger predictor of five-year survival. CONCLUSION: Serum levels of @entity2 have a strong relationship to both volume status and survival in HD @entity0 . We found no clear role for measurement of ANP, though changes in blood levels may be a sensitive indicator of acute changes in volume status. Whether monitoring levels of these peptides has a role in the management of volume status and cardiovascular risk requires further study.

title: The role of natriuretic peptides in volume assessment and mortality prediction in Haemodialysis XXXX .

answer: @entity0


abstract: OBJECTIVE: To evaluate the clinical outcome of surgical management for post-traumatic thoracolumbar @entity4 with @entity1 . METHODS: From March 2007 to May 2010, 17 @entity0 with post-traumatic thoracolumbar kyphotic @entity4 were admitted. The preoperative Cobb angle was 41  -62  (52.5     6.4  ). Sagittal balance was evaluated by the standing lateral films measuring the C7 plumb line distance (C7 PLD) from the posterior superior corner of S1. The C7 PLD was 18-58 (41.2   12.4) mm in the sagittal plane. The preoperative @entity7 index (ODI) was 42-50 (45.7   2.7), and the average preoperative visual analogue scale (VAS) was 8-10 (8.8   0.7). The American @entity8 Association (ASIA) impairment scale was used to assess the @entity3 , and grade C in 1 @entity0 , grade D in 7 and grade E in 9 @entity0 . The operation time, @entity5 , complications, post-operative Cobb angle, ODI and VAS score at the follow-up were collected and analyzed. RESULTS: The average duration of postoperative follow-up was 24-53 (34.5   7.1) months. The operation time was 180-400 (287.1   65.9) min, with an @entity5 of 350-1 300 (838.2   276.4) mL. The postoperative kyphotic angle was 3  -12   (6.1     3.0  ), and it was 7.5     2.6   at the final follow-up evaluation. The postoperative C7PLD was (3.6   3.9) mm and it was (3.4   2.3) mm at the final follow-up evaluation. Postoperatively, the ASIA impairment scale was grade D in 4 and grade E in 13 @entity0 . At the final follow-up ODI and VAS were reduced to an average of 5.2   2.4 and 2.4   1.0, respectively. @entity9 was found in 2 @entity0 , deep wound @entity6 in 1, and @entity2 in 2. All the complications were relieved after conservative medical therapy. One @entity0 received additional surgery at postoperative 12 weeks due to breakage of posterior implants. Another screw pullout case was treated with reinsertion of larger screws at postoperative 4 months. Solid fusion was confirmed by plain film and CT scan in all @entity0 within 1 year after the surgery. CONCLUSION: Single-staged posterior transpedicular limited osteotomies is safe and effective to correct post-traumatic thoracolumbar @entity4 .

title: [Surgical correction of post-traumatic thoracolumbar XXXX with posterior transpedicular limited osteotomy technique].

answer: @entity4


abstract: OBJECTIVE: In @entity0 with severe @entity3 (SBI) median-evoked somatosensory potentials (M-SSEP) serve as a prognostic tool. Bilateral loss of cortical responses (BLCR) is usually thought to be a reliable marker of poor prognosis. Prognostic accuracy to predict a poor outcome depends on the cause of @entity2 and is best in @entity4 ( @entity4 ) reaching almost 100% which is in contrast to @entity0 with other etiologies of @entity2 , especially @entity1 ( @entity1 ). Only little evidence exists on the possibility of electrophysiological recovery of BLCR in repeated or serial SSEP-examinations and detailed functional outcome in these cases. METHODS: 28 @entity0 (78.6% male, 21.4% female, mean age 43.1  18.6 years) from our in- @entity0 early (post-acute) neurorehabilitation center with BLCR in their first M-SSEP were re-examined after a mean interval of 66  55.8 days. SBI was caused by different etiologies. We retrospectively analyzed (a) the recovery rate from BLCR in consecutive M-SSEP and (b) the detailed functional outcome of those @entity0 with recovered cortical responses. RESULTS: 14/28 (50%) @entity0 with primarily BLCR showed re-occurrence of cortical potentials, either uni- or bilaterally. Of the 14 @entity0 , one died due to a non-neurological cause. Of the remaining 13 @entity0 6 - most of them suffering from @entity1 ( @entity1 ) - could be transferred to further continuing neurorehabilitation and achieved good functional long-term outcome. BLCR in @entity4 still had a poor prognosis with none of our @entity0 achieving an outcome better than vegetative state. CONCLUSIONS: Electrophysiological recovery from primarily BLCR seems possible and is accompanied by good functional outcome in a relevant number of @entity0 . Thus caution is warranted in predicting a poor prognosis based predominantly on SSEP, especially in @entity0 with @entity1 . Focusing SSEP-examination on the early days after severe @entity3 and performing only one examination in the case of BLCR may lead to systematic underestimation of the possibility of recovery.

title: Median-evoked somatosensory potentials in severe XXXX : does initial loss of cortical potentials exclude recovery?

answer: @entity3


abstract: BACKGROUND: @entity4 ( @entity4 ) is a rare locoregional disease characterized by disseminated @entity1 . However, little is known about @entity4 from urachal @entity1 as a result of its rarity. METHODS: A total of 9 @entity0 with @entity4 of urachal origin were treated by cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) in our institution. All specimens of surgeries were submitted for pathologic examination. Representative slides of @entity1 and normal urachus were submitted for immunohistochemical staining. RESULTS: Four @entity0 were @entity0 ; the median age was 48  years (range 27-65  years). Initial radiologic examination of all @entity0 showed a @entity1 located between posterior aspect of umbilicus and the dome of urinary bladder, with or without leaking mucin. Complete CRS and HIPEC were performed in all @entity0 . Until the latest follow-up, local recurrence occurred in 1 @entity0 . Other 8 @entity0 had a median disease-free survival of 27.5  months. Primary @entity1 of 9 cases were all mucinous @entity3 . Six @entity0 had low-grade mucinous @entity2 peritonei, and 3 @entity0 had high-grade mucinous @entity2 peritonei. Signet ring cells were noted in 4 @entity0 . All @entity1 specimens of 9 @entity0 were diffusive positive for @entity5 , @entity10 , @entity8 , and @entity7 , and were variant positive for @entity9 . CONCLUSIONS: @entity4 arising from urachus comes from neoplastic cells with development of @entity6 . It shares a similar pathophysiology as @entity4 from appendix. CRS including total urethrectomy, partial cystectomy, and peritonectomy plus HIPEC can be considered as a new option of treatment for @entity4 originating from urachus.

title: Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for XXXX Arising from Urachus.

answer: @entity4


abstract: Health care is embarking on a new era of increased transparency. In January 2015, the Society of Thoracic Surgeons (STS) began to publicly report outcomes of pediatric and congenital cardiac surgery using the 2014 Society of @entity2 Database (STS CHSD) Mortality Risk Model. Because the 2014 STS CHSD Mortality Risk Model adjusts for procedural factors and @entity0 -level factors, it is critical that centers are aware of the important impact of incomplete entry of data in the fields for @entity0 -level factors. These factors are used to estimate expected mortality, and incomplete coding of these factors can lead to inaccurate assessment of case mix and estimation of expected mortality. In order to assure an accurate assessment of case mix and estimate of expected mortality, it is critical to assure accurate completion of the fields for @entity0 factors, including preoperative factors. It is crucial to document variables such as whether the @entity0 was preoperatively ventilated or had an important noncardiac @entity1 . The lack of entry of these variables will lead to an underestimation of expected mortality. The art and science of assessing outcomes of pediatric and congenital cardiac surgery continues to evolve. In the future, when models have been developed that encompass other outcomes in addition to mortality, pediatric and congenital cardiac surgical performance may be able to be assessed using a multidomain composite metric that incorporates both mortality and morbidity, adjusting for the operation performed and for @entity0 -specific factors. It is our expectation that in the future, this information will also be publicly reported. In this era of increased transparency, the complete and accurate coding of both @entity0 -level factors and procedure-level factors is critical.

title: Transparency and Public Reporting of XXXX Outcomes in North America.

answer: @entity2


abstract: BACKGROUND: @entity0 ( @entity0 ) is a rare histologic subtype needing further characterization. The aim of our study was to compare @entity0 to @entity4 ( @entity4 ) of the breast and to identify demographic, clinicopathologic, treatment, and survival differences. METHODS: @entity0 and @entity4 @entity1 were identified using the Surveillance, Epidemiology, and End Results (SEER) public-use data set. @entity3 ( @entity3 ) differences were compared using the Kaplan-Meier method and log-rank tests. Univariate and multivariate Cox proportional hazard models were used to assess factors prognostic for @entity3 . To control for @entity5 status, a subsequent planned analysis was completed for receptor-negative @entity0 and @entity4 . Lastly, a matched case-control analysis was conducted to minimize potential bias due to baseline demographic, clinical, and pathologic differences. RESULTS: The SEER data set included 1,011 @entity0 and 253,818 @entity4 @entity1 diagnosed from 2001 to 2010. @entity0 @entity1 had larger, higher grade @entity2 , had less frequent axillary nodal involvement, and were more likely to be treated with mastectomy. Five-year @entity3 rates were significantly worse for @entity1 with @entity0 than for @entity4 @entity1 (78 vs. 93  %, p  <  0.0001) and for @entity1 with receptor-negative @entity0 than receptor-negative @entity4 (77 vs. 85  %, p  <  0.0001). The findings were confirmed on matched analysis. Prognostic factors identified on multivariate analyses included age, @entity0 histology, @entity2 grade, T stage, and axillary lymph node involvement. CONCLUSIONS: @entity0 @entity1 have shorter @entity3 than @entity4 @entity1 . Improved clinical and biological understanding of @entity0 may result in more effective therapy and better @entity2 outcomes.

title: Survival Outcomes of Metaplastic Breast Cancer XXXX : Results from a US Population-based Analysis.

answer: @entity1